XML 57 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 29, 2017
Aug. 07, 2015
USD ($)
product
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Revenue under collaborative research and development arrangements                 $ 7,409,214 $ 351,272 $ 16,358,316 $ 4,288,586 $ 476,586 $ 2,327,316 $ 1,889,988 $ 1,796,857 $ 28,407,388 $ 6,490,747 $ 26,876,533
Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Upfront payment received             $ 10,000,000                        
MedImmune | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Upfront payment received   $ 27,500,000     $ 27,500,000                            
Additional revenue to be achieved   $ 700,000,000                                  
Number of additional products | product   2                                  
Revenue recognized     $ 7,000,000                                
Revenue under collaborative research and development arrangements                                 22,300,000 1,500,000  
Deferred revenue     1,100,000           1,100,000       13,700,000       1,100,000 13,700,000  
Accounts receivable     1,700,000           1,700,000       1,200,000       1,700,000 1,200,000  
Roche | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Upfront payment received             10,000,000                        
Revenue under collaborative research and development arrangements                                 6,100,000 4,900,000  
Accounts receivable     0           0       2,400,000       0 2,400,000  
Full payment       $ 8,500,000                              
DARPA | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Deferred revenue     149,000           149,000       1,200,000       149,000 1,200,000  
Accounts receivable     $ 4,100,000           $ 4,100,000       $ 9,200,000       4,100,000 9,200,000  
Term           2 years                          
Base award           $ 19,600,000                          
Previously deferred revenue recognized                                 $ 9,800,000 $ 22,400,000  
Option award           24,600,000                          
Second option award           $ 11,100,000                          
ApolloBio | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Territory expansion option period 3 years                                    
INO-3112 | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Revenue recognized   $ 15,000,000                                  
INO 5150 | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Revenue recognized             8,400,000                        
Nonsoftware License Arrangement | License To Research Collaboration Products | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Deferred revenue, additions   $ 12,500,000                                  
Nonsoftware License Arrangement | Option Right | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Deferred revenue, additions             1,500,000                        
Nonsoftware License Arrangement | Joint Steering Committee Obligation | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Deferred revenue, additions             $ 155,000                        
Scenario, Forecast | ApolloBio | Collaborative Arrangement, Product                                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                      
Upfront payment received               $ 23,000,000                      
Additional revenue to be achieved               $ 20,000,000                      
Duration for upfront payment to be made following date of approval of collaborative agreement               3 days                      
Obligation period to pay royalties               10 years